Probe-based fluorescence dosimetry of an antibody-dye conjugate to identify head and neck cancer as a first step to fluorescence-guided tissue preselection for pathological assessment

Naoki Nishio, Stan van Keulen, Nynke S. van den Berg, Guolan Lu, Ethan P. LaRochelle, Scott C. Davis, Brock A. Martin, Shayan Fakurnejad, Quan Zhou, Andrew C. Birkeland, Michael J. Kaplan, Vasu Divi, A. Dimitrios Colevas, Brian W. Pogue, Eben L. Rosenthal*

*Corresponding author for this work

Research output: Contribution to JournalArticleAcademicpeer-review

Abstract

Background: Despite the rapid growth of fluorescence imaging, accurate sampling of tissue sections remains challenging. Development of novel technologies to improve intraoperative assessment of tissue is needed. Methods: A novel contact probe-based fluorescence dosimeter device, optimized for IRDye800CW quantification, was developed. After evaluation of the device in a phantom setup, its clinical value was defined ex vivo in patients with head and neck squamous cell carcinoma who received panitumumab-IRDye800CW. Results: Ten patients were enrolled with a total of 216 data points obtained. Final histopathology showed tumor in 119 spots and normal tissue in 97 spots. Fluorescence-to-excitation ratios in tumor tissue were more than three times higher than those in normal tissue. The area under the curve was 0.86 (95% CI: 0.81-0.91) for tumor detection. Conclusions: Fluorescence-guided tissue preselection using a fluorescence dosimeter could have substantial impact on tissue sampling for frozen section analysis and potentially reduce sampling errors.

Original languageEnglish
Pages (from-to)59-66
Number of pages8
JournalHead and Neck
Volume42
Issue number1
Early online date1 Oct 2019
DOIs
Publication statusPublished - Jan 2020

Bibliographical note

Funding Information:
This work was supported in part by the Stanford Comprehensive Cancer Center, the Stanford University School of Medicine Medical Scholars Program, the Netherlands Organization for Scientific Research (Rubicon; 019.171LW.022), the National Institutes of Health and the National Cancer Institute (R01CA190306), and the Stanford Molecular Imaging Scholars (SMIS) program (T32 CA118681).

Publisher Copyright:
© 2019 Wiley Periodicals, Inc.

Keywords

  • EGFR
  • fluorescence dosimetry
  • fluorescence-guided tissue preselection
  • head and neck cancer
  • panitumumab

Fingerprint

Dive into the research topics of 'Probe-based fluorescence dosimetry of an antibody-dye conjugate to identify head and neck cancer as a first step to fluorescence-guided tissue preselection for pathological assessment'. Together they form a unique fingerprint.

Cite this